PENNVAX-GP is under clinical development by Inovio Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PENNVAX-GP’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 21 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PENNVAX-GP Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PENNVAX-GP overview

PENNVAX-GP is under development for the prevention and treatment of HIV subtypes A, B, C, D infections. It is administered through intradermal and intramuscular route. This vaccine belongs to a family of SynCon DNA-based preventive and therapeutic vaccines for HIV and encodes gag, pol and envelop antigen proteins. The vaccine candidate is based on SynCon DNA vaccine platform and optimized to target two envelope antigens as well as gag and pol antigens using ASPIRE technology, and is delivered using CELLECTRA electroporation based delivery technology.

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; INO-3107 for recurrent respiratory papillomatosis (RRP); and INO-5151 for prostate cancer. The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.

Quick View PENNVAX-GP LOA Data

Report Segments
  • Innovator
Drug Name
  • PENNVAX-GP
Administration Pathway
  • Intradermal
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.